Skip to content
HabitSeek
Back to results

Use sunscreen on exposed skin when UV exposure warrants it

Applying broad-spectrum sunscreen to exposed skin on days when ultraviolet exposure is high enough to matter, as one part of sun protection alongside shade, clothing and timing.

At a glance

  • Evidence: Daily sunscreen use in a randomised trial was followed by about half the melanoma rate and 40 percent fewer squamous cell carcinomas, with no clear effect on basal cell carcinoma.Melanoma, squamous cell carcinoma and skin ageing · Moderate certainty · Randomized intervention
  • What’s uncertain: The cancer trial used SPF 16 in one high-UV Australian town; findings may differ for other skin types, settings or modern formulations.
  • First step: Apply sunscreen to exposed skin before going out, including commonly missed areas such as ears, neck, scalp, hands and feet.
  • Before you try it: Sunscreen is not a reason to extend deliberate tanning or sunbed use. All precautions
Read the full takeaway

Randomized trial

Sunscreen is one of the few cancer-prevention habits tested in a randomised trial rather than only in cohorts. In the Nambour trial in Queensland, adults assigned to daily sunscreen had roughly half the melanoma rate a decade after the trial ended, about 40 percent fewer squamous cell carcinomas over extended follow-up, and 24 percent less skin ageing, while basal cell carcinoma was not clearly reduced and the melanoma hazard ratio of 0.50 had a confidence interval that reached 1.02.

Qualifications and behaviour

Two honest qualifications belong with those numbers. First, a meta-analysis of 29 studies in 313,717 people did not confirm an overall protective association between sunscreen use and skin cancer in the general population; that synthesis is 25 case-control studies out of 29, in which people at highest risk are plausibly the highest users, so it cannot be read as evidence that sunscreen does not work. Second, sunscreen can change behaviour: a systematic review found that when sun exposure is intentional, sunscreen users stayed out 13 to 39 percent longer, and burns were not reliably prevented.

Vitamin D and sun-avoidance findings

The other tension is genuine and unresolved. Experimental work shows sunscreen substantially reduces vitamin D production in skin under artificial ultraviolet, while field trials and observational studies in real-life use show little or no effect on vitamin D status, with the important caveat that no trial has tested the high-SPF products now widely recommended. Cohort data from Sweden go further and associate sun avoidance itself with higher all-cause mortality, but those findings come from one research group, one country, one cohort and one baseline questionnaire, they are acknowledged by their own authors as observational, and they cannot show that seeking sun makes anyone live longer.

A woman applying sunscreen to her face
Long-term healthUnder 10 min · Easy · Low
Reviewed Sep 23, 2026
Save

Scientific evidence

What the research shows

Outcome assessments based on research, including its uncertainties and limitations.

Melanoma, squamous cell carcinoma and skin ageing

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: randomised trials

Daily sunscreen use in a randomised trial was followed by about half the melanoma rate and 40 percent fewer squamous cell carcinomas, with no clear effect on basal cell carcinoma.

Population: 1,621 randomly selected residents of Nambour, Queensland aged 25 to 75 in a randomised trial of daily versus discretionary sunscreen, with 903 adults under 55 contributing the skin-ageing outcome; and 29 observational studies and one controlled trial involving 313,717 participants and 10,670 skin cancer cases in the meta-analysis.

Research details

Summary

In the Nambour trial, 1,621 randomly selected residents of Queensland aged 25 to 75 were assigned in 1992 to daily or discretionary sunscreen application to head and arms alongside beta carotene or placebo, and followed to 2006. Ten years after trial cessation, 11 new primary melanomas had been identified in the daily sunscreen group and 22 in the discretionary group (hazard ratio 0.50; 95% CI 0.24 to 1.02; P = .051), with a larger reduction in invasive melanomas (n = 3 versus 11; HR 0.27; 95% CI 0.08 to 0.97) than in preinvasive melanomas (HR 0.73; 95% CI 0.29 to 1.81). Over extended follow-up of the same trial, squamous cell carcinoma tumour rates were significantly decreased by almost 40 percent (rate ratio 0.62; 95% CI 0.38 to 0.99) while basal cell carcinoma rates tended to decrease but not significantly. A separate analysis of 903 adults under 55 from the same trial found skin ageing from baseline to the end of the trial was 24 percent less in the daily sunscreen group than in the discretionary group (relative odds 0.76; 95% CI 0.59 to 0.98), and beta carotene had no overall effect. Going the other way, a meta-analysis of 29 studies involving 313,717 participants and 10,670 cases found no significant overall association between skin cancer and sunscreen use (OR 1.08; 95% CI 0.91 to 1.28) and stated that its results do not confirm the expected protective benefits of sunscreen against skin cancer in the general population.

Why this certainty

Rated Moderate. Randomised allocation is a genuine strength and is rare in this field, and the direction of effect is consistent across three outcomes measured in the same trial, two of which reached statistical significance. Certainty is not Strong because the evidence rests on one trial in one location with a borderline melanoma result and an imprecise invasive melanoma estimate, and because the largest synthesis of observational data on the same question was null. Certainty is not lower because the trial evidence is randomised, the outcomes are clinical rather than surrogate, and the squamous cell carcinoma and skin-ageing findings are supported by the same randomised comparison.

Limitations

The randomised evidence comes from a single trial in one high-ultraviolet Australian township, so it may not transfer to lower-ultraviolet settings, to different skin types, or to modern higher-SPF formulations; the trial product was an SPF 16 broad-spectrum sunscreen applied to head, neck, hands and forearms only. The melanoma result did not reach conventional statistical significance (P = .051) and its confidence interval reached 1.02, and the invasive melanoma analysis rested on 3 events in the active group against 11 in the control group. The skin-ageing analysis had some outcome data missing and, by the authors' own statement, only modest power to detect moderate treatment effects. The meta-analysis that found no protective association is composed almost entirely of case-control studies, in which people at highest risk of skin cancer are also the highest users of sunscreen, so its null result cannot be read as evidence that sunscreen does not work. No randomised trial has tested melanoma incidence as a primary endpoint in a general population.

Effect estimate

Daily versus discretionary sunscreen: melanoma hazard ratio 0.50 (95% CI 0.24-1.02) at 10 years after trial cessation; squamous cell carcinoma rate ratio 0.62 (95% CI 0.38-0.99) over extended follow-up; skin ageing relative odds 0.76 (95% CI 0.59-0.98).

Sources for this outcome:

Vitamin D status and all-cause mortality

Finding: Insufficient direct evidenceCertainty: Limitedthis has not been directly tested

Evidence basis: observational studies (association, not proof of cause)

Real-life sunscreen use does not appear to lower vitamin D, but no trial has tested modern high-SPF products, and cohort data raising mortality concerns about sun avoidance are heavily confounded.

Population: Four experimental studies, three field trials (two randomised) and 69 observational studies for the vitamin D question, plus a 13-expert international consensus panel; and 29,518 Swedish women aged 25 to 64 at recruitment in 1990-1992 followed prospectively for 20 years with 2,545 deaths for the mortality question.

Research details

Summary

A systematic review of four experimental studies, three field trials including two randomised controlled trials, and 69 observational studies found that sunscreen considerably abrogated vitamin D3 or 25(OH)D production under artificially generated ultraviolet radiation, while the randomised controlled field trials found no effect of daily sunscreen application on vitamin D and most observational studies found no association or found that self-reported sunscreen use was associated with higher 25(OH)D concentration. The authors concluded there is little evidence that sunscreen decreases 25(OH)D in real-life settings, but flagged that there have been no trials of the high-SPF sunscreens now widely recommended. An international expert consensus reached a similar position, stating that broad-spectrum sunscreens which prevent erythema are unlikely to compromise vitamin D status in healthy populations, and that sunscreen use for daily and recreational photoprotection does not compromise vitamin D synthesis even under optimal conditions, while warning that photoprotection strategies for patients with photosensitivity disorders are likely to compromise vitamin D status and that this group should be screened and supplemented. On the other side of the tension, in the Melanoma in Southern Sweden cohort of 29,518 women followed for 20 years, women with active sun exposure habits were mainly at lower risk of cardiovascular and noncancer/non-CVD death, non-smokers who avoided sun exposure had a life expectancy similar to smokers in the highest sun exposure group, and the life expectancy of sun avoiders was reduced by 0.6 to 2.1 years. The Swedish cohort's twofold mortality difference between sun avoiders and the highest sun exposure group corresponds to a population attributable risk of only 3%, which is how small the population-level quantity is despite the large relative difference.

Why this certainty

Rated Limited, and the outcome is recorded as Insufficient direct evidence rather than as a benefit or a harm. The vitamin D question has randomised field trials, but only with moderate-SPF products, and the mortality question has no randomised evidence at all. Certainty is not lower because the vitamin D findings are consistent between an expert consensus and a systematic review that includes randomised trials, and because the mortality cohort is large with long follow-up. Certainty cannot be higher because the exposure measurement is weak, the confounding is structural rather than incidental, and the mortality association has never been tested experimentally.

Limitations

The vitamin D field trials that found no effect used sunscreens with only moderate protection, around SPF 16, so the question is genuinely open for the high-SPF products people now buy; the experimental studies showing reduced vitamin D synthesis used artificial ultraviolet with a spectral output unlike terrestrial sunlight. For the mortality findings, sun exposure habits were self-reported and measured once at baseline, so long-term exposure is misclassified, and the comparison between sun avoiders and sun seekers is confounded by health status, physical activity, outdoor occupation, skin type, smoking, alcohol and socioeconomic position, with reverse causation a serious concern because illness reduces time outdoors. The mortality data come from a single cohort in one country studied by one research group, with a healthy participant effect and limited ethnic and skin-type diversity, and no randomised trial has tested sun exposure or sun avoidance against mortality. The authors of the vitamin D review state plainly that no adequate evidence exists for the sunscreens now widely recommended.

Sources for this outcome:

What people say

Who discusses this?

Public statements, with positions specific to each source and topic. These views do not determine the scientific evidence assessment.

What the research shows ↑

No sourced public statements added for this habit yet. This does not mean no one discusses it.

Practical steps and precautions

How to try it

  1. Apply sunscreen to exposed skin before going out rather than after you notice burning, and cover the places that are routinely missed: ears, neck, scalp where hair is thin, backs of hands and feet, and the tops of the feet.
  2. Treat sunscreen as one layer of protection rather than the whole strategy, and pair it with shade, clothing and avoiding the middle of the day when ultraviolet index is highest; the trial evidence is for sunscreen used as part of ordinary sun protection, not as a substitute for it.
  3. Reapply after swimming, heavy sweating and towelling, because the protection on the label assumes an application thickness that people rarely achieve in practice.
  4. Do not use sunscreen to buy extra time in the sun. If you are deliberately sunbathing for a tan, sunscreen is not fixing that decision, and the retrieved review evidence links intentional sun exposure with longer time spent outdoors rather than with fewer burns.

Precautions

  • Sunscreen is not a reason to extend deliberate tanning or sunbed use. Intentional sun exposure with sunscreen was associated with 13 to 39 percent longer time in the sun in a systematic review, and ultraviolet radiation including sunbed use is classified as carcinogenic to humans.
  • If you have a photosensitivity disorder or take a photosensitising medicine, you need rigorous photoprotection including high-SPF sunscreen, clothing and shade, and you should have vitamin D status checked and supplemented as advised, because in this group photoprotection is likely to compromise vitamin D status.
  • Do not treat sunscreen as sufficient on its own. The randomised evidence comes from one trial of an SPF 16 product applied to head, neck, hands and forearms in a high-ultraviolet setting, and basal cell carcinoma was not clearly reduced, so unprotected skin elsewhere is not covered by the trial result.
  • Sun avoidance carries its own unresolved questions. Cohort studies from Sweden associate avoidance of sun exposure with higher all-cause mortality, and the retrieved evidence cannot say whether that is causal; if you are deliberately avoiding all sun for health reasons, it is reasonable to discuss vitamin D intake with a clinician rather than assuming avoidance is cost-free.

References

Reduced melanoma after regular sunscreen use: randomized trial follow-up.

Green AC, Williams GM, Logan V, Strutton GM · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011

Randomised controlled trial with 10-year post-trial follow-upVerified from abstract
Open original source

Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use.

van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC · Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2006

Randomised controlled trial with 8 years of post-trial follow-upVerified from abstract
Open original source

Sunscreen and prevention of skin aging: a randomized trial.

Hughes MC, Williams GM, Baker P, Green AC · Annals of internal medicine · 2013

Randomised controlled community-based trialVerified from abstract
Open original source

Use of sunscreen and risk of melanoma and non-melanoma skin cancer: a systematic review and meta-analysis.

Silva ESD, Tavares R, Paulitsch FDS, Zhang L · European journal of dermatology : EJD · 2018

Systematic review and meta-analysis of observational studies and controlled trialsVerified from abstract
Open original source

Sunscreen use and increased duration of intentional sun exposure: still a burning issue.

Autier P, Boniol M, Doré JF · International journal of cancer · 2007

Systematic review of observational studies and randomised trialsVerified from abstract
Open original source

The effect of sunscreen on vitamin D: a review.

Neale RE, Khan SR, Lucas RM, Waterhouse M, Whiteman DC, Olsen CM · The British journal of dermatology · 2019

Systematic review of experimental studies, field trials and observational studiesVerified from abstract
Open original source

Sunscreen photoprotection and vitamin D status.

Passeron T, Bouillon R, Callender V, Cestari T, Diepgen TL, Green AC, van der Pols JC, Bernard BA, Ly F, Bernerd F, Marrot L, Nielsen M, Verschoore M, Jablonski NG, Young AR · The British journal of dermatology · 2019

International expert consensus review of published evidenceVerified from full text
Open original source

Avoidance of sun exposure as a risk factor for major causes of death: a competing risk analysis of the Melanoma in Southern Sweden cohort.

Lindqvist PG, Epstein E, Nielsen K, Landin-Olsson M, Ingvar C, Olsson H · Journal of internal medicine · 2016

Prospective cohort study with competing risk analysisVerified from abstract
Open original source

Avoidance of sun exposure is a risk factor for all-cause mortality: results from the Melanoma in Southern Sweden cohort.

Lindqvist PG, Epstein E, Landin-Olsson M, Ingvar C, Nielsen K, Stenbeck M, Olsson H · Journal of internal medicine · 2014

Prospective cohort studyVerified from abstract
Open original source

Community

Discussion

Have you tried this? What helped or made it difficult?

Reader experiences are separate from the scientific evidence. Explore all discussions

No discussions yet.

Be the first to ask a question or share your experience.

Sign in to vote or join the discussion.

Related habits

Explore other habits in a shared category. Each has its own evidence and precautions.

Editorial history and review method

Revision 3 · Approved for publication · Codex (publication approval explicitly authorized by site owner; category migration)

Prepared and checked with AI. Publication approval does not imply independent expert review. Request a correction.

Audit correction pass (group 6). Verdict corrected: the sentence previously attributed to silva-2018 the reasoning that 'those at highest risk are naturally the highest users, so observational data on this question are structurally confounded'. That reasoning is not in the retrieved record, which reports only that the meta-analysis 'does not confirm the expected protective benefits of sunscreen against skin cancer in the general population', the cumulative odds ratio before the 1980s of 2.35 (1.66 to 3.33) falling to non-significance from the early 1990s, and the composition of 25 case-control, 2 cohort, 1 cross-sectional and 1 controlled trial. The verdict now states the composition as fact and the confounding as the catalogue's own reading, matching the wording already used in limitations. No number changed. A second reviewer must re-check: (1) that the vitamin-d-and-mortality outcome is still recorded as Insufficient direct evidence with a null effect estimate, since the audit flagged it as bundling a directly tested randomised question (sunscreen and 25(OH)D) with an untested one (sunscreen and mortality) — this correction pass deliberately did not restructure it, because splitting it changes the outcome list of a Standard-coverage entry whose card outcome is the skin-cancer outcome, and the audit presented the restructure as a recommendation rather than as a wrong number; (2) that the skin cancer headline still flags the melanoma confidence interval reaching 1.02; and (3) that the Swedish cohorts' 3% population attributable risk is still not quoted in reader-facing text. Publication release 2026-10-04: site owner authorized a bounded AI audit and release of this exact revision. See docs/release-audit-2026-10-04.md for source-check findings and limits. No independent health-professional or peer review is claimed. Category migration 2026-10-04: removed the separate goals field; categories: Long-term health → Long-term health. Research assessments, sources, guidance, precautions, and evidence review dates are unchanged. This revision awaits publication approval; no new evidence review is claimed. Publication approval 2026-10-04: site owner explicitly accepted all current category-migration revisions for deployment and requested that remaining limitations be retained in docs/content-review-backlog.md. Approval applies to this exact content revision. No new evidence review, independent expert review, or clinical validation is claimed; existing precautions and disclosures remain in effect.